published the first prospective clinical trial (ECOG 1684) indicating a significant increase in survival for patients with T4 or N1 melanoma treated with adjuvant high-dose interferon alpha-2b (IFN-α-2b; Kirkwood et al, 1996). Nevertheless, this treatment was associated with moderate to severe side-effects for a long time during and after treatment (Cole et al, 1996; Kirkwood et al, 1996). Therefore, apart from the issue of the indication for such a treatment, and while waiting for the results of the forthcoming trial ECOG 1690, we planned to treat patients with T4 or N1 melanoma who were referred to our institutions with the identical ECOG 1684 treatment, and to evaluate prospectively the tolerance and feasibility of this treatment outside a clinical trial.
week for 11 months (consolidation phase) (Kirkwood et al, 1996) . The treatment had to start less than 6 weeks after the definitive surgical treatment.
Toxicity was evaluated using the World Health Organization (WHO) grading criteria. All patients received paracetamol and anti-emetics for the first few days to prevent fever and nausea or vomiting. Thereafter, symptomatic treatment was tailored to toxicity. Haematological and hepatic parameters were checked 1-3 times a week during the induction phase and 1-4 times a month during the consolidation phase. Patients were seen by the physicians weekly in the induction phase and monthly during the consolidation phase. No mandatory dose modification was planned but particular care was recommended for severe psychiatric disorders, grade 3 increase in transaminases and grade 4 neutropenia. Thyroid function was checked every 3-6 months during treatment.
RESULTS
Thirty-six patients started treatment between March 1996 to December 1997. Thirty-four patients had a N1 disease, of these, 31 had an extensive regional nodal dissection, one patient had a T4 disease and another had been treated for a single metastatic lesion by surgery. The median age was 54, with a range from 8 to 75 years old.
Induction phase
During the induction phase, 17 patients received 100% and 24 (66.6%) more than 80% of the planned dose (Table 1) . Thirteen patients (36.1%) experienced grade 3 toxicity while five patients Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice (13.9%) experienced grade 4 toxicity. The main clinical toxicities were asthenia, fever, nausea, vomiting and psychiatric disorders ( Table 2 ). All except six patients developed neutropenia, with grade 3 or 4 toxicity in 12 patients. Five patients had grade 3 hepatic cytotoxicity. Seventeen patients (47.2%) required either discontinuation or dose reduction because of toxicity.
Consolidation phase
For the purpose of analysis, the maintenance phase was divided into four time periods: 1-3 months, 4-6 months, 7-9 months and 10-11 months (Tables 3 and 4 ). All patients were considered for toxicity.
The reasons for discontinuation of treatment were disease progression (14 patients) and toxicity (five patients) (Table 3) . Another patient had a pregnancy after 9 months of treatment.
From months 1-3 of the consolidation treatment, 23/34 patients received 100% of the planned dose of IFN-α, while 17/31, 13/26 and 7/17 patients did so in the subsequent consolidation phases respectively (Table 1) .
Seven patients had at least a grade 4 toxic event and nine at least grade 3 side-effects related to treatment during the overall consolidation phase. The most frequent severe clinical side-effects were asthenia and psychiatric disorders, while neutropenia and an increase in transaminases were the most frequent severe treatmentrelated biological changes (Table 4) . Any side-effects were regularly reported irrespective of the period. Throughout the consolidation treatment, 19/34 patients (55.8%) who started the consolidation phase had either a dose reduction or discontinued therapy due to toxicity.
End of treatment
Sixteen patients (44.4%) among the 36 initial patients completed the treatment after 12 months of IFN-α-2b.
DISCUSSION
Owing to the results of the ECOG 1684 study (Kirkwood et al, 1996) , IFN-α-2b is now licensed for use as adjuvant therapy in patients with a high-risk melanoma. Although this treatment cannot be considered as standard until the results are confirmed by another trial (ECOG 1690), we felt it was useful to test whether this treatment is feasible in terms of schedule, dose and toxicity outside the reference trial.
In comparison to the initial study of the ECOG, our results do not differ for the total given dose of IFN-α-2b, for toxicity or for the incidence of disease progression during treatment.
Whereas in the ECOG 1684 study (Kirkwood et al, 1996) , 72.7% of patients received more than 80% of the theoretical dose, 66.6% did so in our study during the induction phase. Nevertheless, this period needs a thorough clinical and biological follow-up to check for the occurrence of grade 3 or 4 toxicity which was encountered by 50% of our patients and at least in 37% in the ECOG study (Kirkwood et al, 1996) .
Significant toxicity was also seen in the consolidation phase, as 16 patients (47%) experienced a grade 3 or 4 toxicity, a similar figure to that in the ECOG study.
CONCLUSION
Adjuvant treatment with high-dose IFN-α-2b for patients with malignant cutaneous melanoma, as reported by ECOG (Kirkwood al, 1996) , is feasible. Our results do not differ from those of the reference study in terms of schedule and the dose given of IFN-α-2b. Moreover, the significant toxicity reported by Kirkwood was also seen in our study. 
